Share on LinkedInShare on LinkedIn

ARTICLE · 16 OCTOBER 2024

Medicare Coverage: CMS Finalizes New Pathway For Breakthrough Devices

The Centers for Medicare & Medicaid Services (CMS) released a Final Notice for Transitional Coverage for Emerging Technologies (TCET)...

United StatesFood, Drugs, Healthcare, Life Sciences

The Centers for Medicare & Medicaid Services (CMS) released a Final Notice for Transitional Coverage for Emerging Technologies (TCET), effective August 12, 2024, to provide "transparent, predictable, and expedited national coverage" for eligible devices designated as "breakthrough devices" by the U.S. Food & Drug Administration (FDA). FDA-designated breakthrough devices are devices that FDA has determined provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. As CMS noted in the background section to the Final Notice, the TCET pathway is intended to provide a clear, transparent, and consistent coverage process for these devices.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from